{"entity":{"id":"nct02138734","kind":"trial","name":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","aka":[],"tldr":"A phase 1/2 trial of BCG (50mg/instillation) + N-803 (400 μg/instillation) in bladder & urothelial cancer, run by ImmunityBio, Inc., active and no longer recruiting.","summary":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT02138734 by ImmunityBio, Inc., with 369 participants enrolled, started 2014-07-21 and due to reach its primary completion in 2026-09-30. Interventions recorded: BCG (50mg/instillation) + N-803 (400 μg/instillation) and BCG (50mg/instillation).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02138734","url":"https://clinicaltrials.gov/study/NCT02138734"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02138734","phase":"1/2","setting":"A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer","sponsor":"ImmunityBio, Inc.","enrolled":369,"outcomes":[]},"route":"/trials/nct02138734/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}]}}